JP2025502861A5 - - Google Patents
Info
- Publication number
- JP2025502861A5 JP2025502861A5 JP2024540670A JP2024540670A JP2025502861A5 JP 2025502861 A5 JP2025502861 A5 JP 2025502861A5 JP 2024540670 A JP2024540670 A JP 2024540670A JP 2024540670 A JP2024540670 A JP 2024540670A JP 2025502861 A5 JP2025502861 A5 JP 2025502861A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- sucrose
- fxi
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210006206.X | 2022-01-05 | ||
| CN202210006206 | 2022-01-05 | ||
| CN202210053441 | 2022-01-18 | ||
| CN202210053441.2 | 2022-01-18 | ||
| PCT/CN2023/070573 WO2023131213A1 (zh) | 2022-01-05 | 2023-01-05 | 一种包含抗FXI/FXIa抗体的药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025502861A JP2025502861A (ja) | 2025-01-28 |
| JP2025502861A5 true JP2025502861A5 (cg-RX-API-DMAC10.html) | 2026-01-15 |
Family
ID=87073189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540670A Pending JP2025502861A (ja) | 2022-01-05 | 2023-01-05 | 抗FXI/FXIa抗体を含む医薬組成物及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250179213A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4461749A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025502861A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118382643A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202333789A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023131213A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11066481B2 (en) * | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
| TW201802121A (zh) * | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| PT3570882T (pt) * | 2017-01-19 | 2022-01-11 | Bayer Pharma AG | Nova formulação estável para anticorpos fxia |
| RU2766590C2 (ru) * | 2017-05-16 | 2022-03-15 | Цзянсу Хэнжуй Медисин Ко., Лтд. | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение |
| EP3713965A1 (en) * | 2017-11-22 | 2020-09-30 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| WO2020008022A1 (en) * | 2018-07-05 | 2020-01-09 | Bayer Aktiengesellschaft | METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY |
| CN110732023B (zh) * | 2018-07-18 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 一种her2抗体药物组合物及其用途 |
| US12703762B2 (en) * | 2018-12-18 | 2026-08-11 | Novartis Ag | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
| EP3957652A4 (en) * | 2019-04-16 | 2023-06-21 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-fxi/fxia antibody and use thereof |
| JP2023507795A (ja) * | 2019-12-20 | 2023-02-27 | アントス セラピューティクス, インコーポレイテッド | 第XI/XIa因子抗体の医薬製剤および投薬レジメン |
| BR112022026533A2 (pt) * | 2020-07-02 | 2023-01-17 | Beijing Tuo Jie Biopharmaceutical Co Ltd | Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo |
-
2023
- 2023-01-05 EP EP23737076.2A patent/EP4461749A4/en active Pending
- 2023-01-05 TW TW112100422A patent/TW202333789A/zh unknown
- 2023-01-05 JP JP2024540670A patent/JP2025502861A/ja active Pending
- 2023-01-05 WO PCT/CN2023/070573 patent/WO2023131213A1/zh not_active Ceased
- 2023-01-05 US US18/726,599 patent/US20250179213A1/en active Pending
- 2023-01-05 CN CN202380015149.4A patent/CN118382643A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240398914A1 (en) | Combination therapy using a factor xii inhibitor and a c-1 inhibitor | |
| TW201420601A (zh) | 抗tslp抗體之安定調配物 | |
| JP2024508762A5 (cg-RX-API-DMAC10.html) | ||
| JP2024506940A5 (cg-RX-API-DMAC10.html) | ||
| JP2022532927A5 (cg-RX-API-DMAC10.html) | ||
| US12251474B2 (en) | Process for lyophilized pharmaceutical formulations of a therapeutic protein | |
| JP2017536414A5 (cg-RX-API-DMAC10.html) | ||
| US11498961B2 (en) | SOST antibody pharmaceutical composition and uses thereof | |
| CN110234353A (zh) | 用于FXIa抗体的新型稳定制剂 | |
| WO2021127525A1 (en) | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies | |
| WO2018223958A1 (zh) | 一种含c-Met抗体药物偶联物的药物组合物及其用途 | |
| JP2024001135A (ja) | Ttpの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法 | |
| CN119677508A (zh) | 与抗因子xi/因子xia抗体的组合疗法 | |
| KR20230035355A (ko) | 인자 xii 항원 결합 단백질의 고농도 제형 | |
| JP2025506427A (ja) | 生物学的製剤の経口送達のための組成物 | |
| WO1994022471A1 (fr) | Preparation liquide d'antithrombine iii et procede pour sa stabilisation | |
| JP2024508746A5 (cg-RX-API-DMAC10.html) | ||
| CN106459208B (zh) | Tafi和pai-1的双重靶向 | |
| TW202333789A (zh) | 一種包含抗FXI/FXIa抗體的醫藥組成物及其用途 | |
| JP2025521231A5 (cg-RX-API-DMAC10.html) | ||
| JP2024543931A5 (cg-RX-API-DMAC10.html) | ||
| RU2775692C2 (ru) | Новые стабильные композиции для fxia антител | |
| CN118078988A (zh) | 包含靶向il-17a的抗体药物组合物 | |
| WO2023098694A1 (zh) | 一种抗sost抗体药物组合物及其用途 | |
| RU2020102952A (ru) | Фармацевтическая композиция, содержащая антитела к pcsk-9, и ее применение |